Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA as Marker for Response to Antineoplastic Treatment of Metastatic Cancer (FLUIDO)

NCT04793061 is registered in ClinicalTrials.gov with Elisabethinen Hospital as lead sponsor.

NCT NCT04793061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04793061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA as Marker for Response to Antineoplastic Treatment of Metastatic Cancer (FLUIDO)
Lead sponsor
Elisabethinen Hospital
Phase
Observational
Overall status
Unknown status
Start date
April 1, 2021
Completion date
November 30, 2022
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer